Precigen Inc
F:I5X
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Precigen Inc
F:I5X
|
US |
|
China State Construction International Holdings Ltd
OTC:CCOHF
|
HK |
|
R
|
Riber SA
XBER:RI7
|
FR |
|
S
|
Sino Land Co Ltd
OTC:SNLAY
|
HK |
|
Brookfield Corp
NYSE:BN
|
CA |
|
Gold Fields Ltd
OTC:GFIOF
|
ZA |
|
Sony Group Corp
OTC:SNEJF
|
JP |
|
T
|
Turkcell Iletisim Hizmetleri AS
XBER:TUL1
|
TR |
|
A
|
Align Technology Inc
DUS:AFW
|
US |
|
J
|
JCDecaux SE
SWB:DCS
|
FR |
|
A
|
Advanced Micro Devices Inc
XETRA:AMD
|
US |
|
I
|
International Consolidated Airlines Group SA
SWB:INR
|
UK |
|
Nippon Sanso Holdings Corp
OTC:TYNPF
|
JP |
Precigen Inc
Precigen is a biotechnology company that builds gene and cell therapies for serious diseases, especially cancer, immune disorders, and infectious diseases. It develops its own therapy platforms and drug candidates rather than selling a physical product line, so its work is centered on research, lab development, and clinical testing. The people who matter most to its business are patients, hospitals, and eventually the doctors who prescribe approved treatments, along with larger drug companies that may partner on development. The company makes money mainly by advancing drug programs, partnering with other biotech or pharmaceutical companies, and licensing out its technology when it can. In a business like this, the value comes from owning useful therapy platforms and intellectual property, then turning those into licensed programs or approved medicines. That means Precigen sits closer to the early, high-risk end of the drug pipeline than a traditional drug seller. What makes its role different is that it is not a broad drugmaker with many marketed medicines. It is a platform-based biotech focused on creating new treatment methods from engineered cells and genes, which can be used to design highly specific therapies. Investors should think of it as a company trying to convert scientific technology into future medicines and partnership value.
Precigen is a biotechnology company that builds gene and cell therapies for serious diseases, especially cancer, immune disorders, and infectious diseases. It develops its own therapy platforms and drug candidates rather than selling a physical product line, so its work is centered on research, lab development, and clinical testing. The people who matter most to its business are patients, hospitals, and eventually the doctors who prescribe approved treatments, along with larger drug companies that may partner on development.
The company makes money mainly by advancing drug programs, partnering with other biotech or pharmaceutical companies, and licensing out its technology when it can. In a business like this, the value comes from owning useful therapy platforms and intellectual property, then turning those into licensed programs or approved medicines. That means Precigen sits closer to the early, high-risk end of the drug pipeline than a traditional drug seller.
What makes its role different is that it is not a broad drugmaker with many marketed medicines. It is a platform-based biotech focused on creating new treatment methods from engineered cells and genes, which can be used to design highly specific therapies. Investors should think of it as a company trying to convert scientific technology into future medicines and partnership value.
Launch momentum: PAPZIMEOS generated $21.6 million of net product revenue in Q1 2026, up sharply from $3.4 million in Q4 2025, as management said demand continued to accelerate into Q2.
Broad access: Management said payer coverage is now extensive, with about 297 million lives covered and more than 90% of insured U.S. lives covered, helped by the permanent J-code.
Commercial expansion: The company said the drug is gaining traction in both major medical centers and community practices, with about 400 patients registered in the hub and 25% coming from the community setting.
Financial discipline: Total revenue was $23.3 million and operating loss was only $6 million, while the company ended the quarter with $56.7 million in cash, cash equivalents and investments.
Outlook: Management declined to give formal quarterly guidance but said Q2 revenue and cash use should improve, and reiterated it expects to reach cash flow breakeven by the end of 2026 without needing to raise capital.
Pipeline update: Precigen plans to start a pediatric PAPZIMEOS trial in Q4, continue the EMA review, present durability data at ASCO next month, and share PRGN-2009 Phase II data in the second half of the year.
